Navigation Links
Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
Date:1/17/2008

FLINT, Mich., Jan. 17 /PRNewswire/ -- Diplomat Specialty Pharmacy, one of the largest privately owned national specialty pharmacies, announced today that it has entered into an agreement with Genzyme Corporation to administer their 2008 Renagel Medicare Part D Assistance Program. Genzyme is one the world's largest biotechnology companies dedicated to products and services focused in kidney disease, rare inherited disorders, orthopedics, transplant, and oncology.

Diplomat will be the 2008 national Part D Assistance provider for Renagel(R) (sevelamer hydrochloride). Renagel is a non-calcium/non-metal based phosphorus binder indicated for the control of serum phosphorus in patients with Chronic Kidney Disease (CKD) on dialysis. The Renagel Part D Assistance Program provides Renagel free of charge to patients who are enrolled in a Medicare Prescription Drug Plan but cannot afford their copayments or co-insurance payments for Renagel. The Renagel Part D Assistance program complements Diplomat's existing renal program which includes pharmacy delivery of required medications to dialysis patients and CKD disease management.

"Genzyme Corporation selected Diplomat Specialty Pharmacy to administer our 2008 Renagel Medicare Part D Assistance Program because of their understanding of the renal sector and reputation for providing a high level of customer service for over 30 years," stated Robin Goldwater, Director of Reimbursement & Specialty Services of Genzyme Corporation. "Our group will work closely with the Diplomat team to help qualified patients receive free Renagel.

"Diplomat is honored to be chosen as Genzyme's pharmacy partner for the 2008 Renagel Medicare Part D Assistance program," stated Phil Hagerman RPh, President/CEO of Diplomat Specialty Pharmacy. "Diplomat's experience and commitment to patients with Chronic Kidney Disease will help support Genzyme's premier national renal program that will assist dialysis patients to gain access to required medications and achieve optimal clinical outcomes."

Those interested in more information or in applying to the Program should contact Genzyme's Renassist Program at 1-800-847-0069.

About Diplomat Specialty Pharmacy

Diplomat Specialty Pharmacy is a privately held health care organization focusing on complete medication management programs for patients with serious and chronic conditions. Key programs include: Oncology, HIV/AIDS, Hepatitis C, Multiple Sclerosis, Rheumatoid Arthritis and Psoriasis. Other specialty areas include Transplant, Fertility, Dialysis Medication Management, Bio- Identical Hormone Replacement Therapy and Specialty Compounding. The company's Health Services division specializes in disease management programs for Chronic Kidney Disease patients, as well as home and outpatient infusion. With locations in Flint and Grand Rapids, MI; Cleveland, OH; Chicago, IL; and Ft. Lauderdale, Florida; Diplomat services the specialty pharmacy needs of patients and physicians nationwide.

For more information contact:

Kathy Karns

kkarns@diplomatpharmacy.com

810-720-4452


'/>"/>
SOURCE Diplomat Specialty Pharmacy
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
2. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
3. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
4. CEL-SCI Corporation Announces 2007 Financial Results
5. Berkery Noyes Represented The Thomson Corporation in the Sale of CenterWatch and New England Institutional Review Board to Jobson Medical Information
6. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
7. Immunosyn Corporation Releases SF-1019 Study Results
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
9. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
10. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
11. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , Tenn. and DALLAS , April 19, ... Inc., announced that the first patients in ... EndoStim device in the Lower Esophageal Sphincter Stimulation for ... minimally-invasive implantable device designed to provide long-term reflux control ... GERD affects nearly 65 million people in ...
(Date:4/19/2017)... , April 19, 2017  Novartis today announced ... National Heart, Lung, and Blood Institute (NHLBI) of ... 58% of patients with treatment-na├»ve severe aplastic anemia ... treated with eltrombopag at the initiation of and ... study evaluated three sequential treatment groups, or cohorts. ...
(Date:4/18/2017)... 18, 2017 Research and Markets has announced ... report to their offering. ... global arthroscopy devices market to grow at a CAGR of 6.35% ... Devices Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... The Radiology Business Management Association (RBMA) is pleased to announce ... process has been in place since the RBMA was founded in 1968 with all ... Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer for ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... and College of Urgent Care Medicine will host industry leaders for the annual ... will help those in the industry adapt to the issues currently affecting urgent ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... skincare and advanced nutraceutical supplements, through its Nova Skin Sciences division, recently ... hydrating benefits of a moisturizer with the power of an anti-aging concentrate. ...
(Date:4/28/2017)... ... 2017 , ... Christie Medical Holdings, Inc. , with its market-leading ... Medical Inc. , a leader in infusion therapy and pain management. , Intravenous ... percent of hospital patients receiving a peripheral IV catheter as part of their treatment ...
Breaking Medicine News(10 mins):